Subdural haematoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Subdural haematoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Early vs. Late Restart of Anticoagulation with Edoxaban, Apixaban, and Warfarin for Patients with Chronic Subdural Hematoma and Atrial Fibrillation https://clinicaltrials.eu/trial/study-on-early-vs-late-restart-of-anticoagulation-with-edoxaban-apixaban-and-warfarin-for-patients-with-chronic-subdural-hematoma-and-atrial-fibrillation/ Wed, 29 Apr 2026 15:05:10 +0000 https://clinicaltrials.eu/trial/study-on-early-vs-late-restart-of-anticoagulation-with-edoxaban-apixaban-and-warfarin-for-patients-with-chronic-subdural-hematoma-and-atrial-fibrillation/ This clinical trial is focused on studying the effects of restarting blood-thinning medications, known as anticoagulants, in patients who have undergone surgery for a condition called chronic subdural hematoma and also have atrial fibrillation. Chronic subdural hematoma is a condition where blood collects on the surface of the brain, often requiring surgical intervention. Atrial fibrillation is a common heart rhythm disorder that can increase the risk of stroke. The trial will compare the outcomes of starting these medications early versus later after surgery.

The medications being studied include Edoxaban, Apixaban, Warfarin, Dabigatran Etexilate, and Rivaroxaban. These are all oral anticoagulants, which means they are taken by mouth to help prevent blood clots. The purpose of the study is to understand the overall effects of these medications when resumed at different times after surgery, focusing on events like stroke, bleeding, and death related to blood vessels.

Participants in the study will be randomly assigned to either restart their anticoagulation medication early or later after their surgery. The study will monitor various health outcomes over a period of time to determine the best approach for managing anticoagulation in these patients. The trial aims to provide valuable information that could help improve treatment strategies for individuals with both chronic subdural hematoma and atrial fibrillation.

]]> Study on Tranexamic Acid to Prevent Surgery in Patients with Chronic Subdural Hematoma https://clinicaltrials.eu/trial/study-on-tranexamic-acid-to-prevent-surgery-in-patients-with-chronic-subdural-hematoma/ Wed, 29 Apr 2026 14:59:09 +0000 https://clinicaltrials.eu/trial/study-on-tranexamic-acid-to-prevent-surgery-in-patients-with-chronic-subdural-hematoma/ This clinical trial is focused on studying a condition known as Chronic Subdural Hematoma (cSDH). This condition involves the collection of blood on the brain’s surface, often due to minor head injuries, and can lead to symptoms like headaches, confusion, and weakness. The study is investigating the use of a medication called Tranexamic Acid, which is taken in capsule form. Tranexamic Acid is an antifibrinolytic, meaning it helps prevent the breakdown of blood clots, which might help reduce the need for surgery in patients with cSDH.

The purpose of this study is to determine if patients with cSDH who receive Tranexamic Acid as a primary conservative treatment are less likely to require surgery within 12 weeks compared to those who receive a placebo. Participants in the study will be monitored over a period of time to see if the medication helps in managing their condition without the need for surgical intervention.

Throughout the study, participants will take Tranexamic Acid orally, and their progress will be observed to assess the effectiveness of the treatment. The study aims to provide valuable insights into whether this medication can be a viable option for reducing the need for surgery in patients with chronic subdural hematoma.

]]>